Posted by Michael Wonder on 16 Sep 2017
Janssen receives CHMP positive opinion for guselkumab recommending approval for the treatment of moderate to severe plaque psoriasis in the European Union
15 September 2017 - Pending approval, guselkumab will be the first biologic that selectively blocks interleukin-23.
Janssen-Cilag announced today that the CHMP adopted a positive opinion recommending marketing authorisation in the European Union for the use of guselkumab in the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy.
The EU filing is based primarily on data from three Phase III clinical studies.
